Assessment of Esophageal Epithelium Integrity With Mucosal Impedance
- Conditions
- Gastroesophageal Reflux Disease (GERD)Non-erosive Reflux Disease (NERD)
- Registration Number
- NCT02318862
- Lead Sponsor
- Vanderbilt University Medical Center
- Brief Summary
Gastroesophageal reflux disease (GERD) is a common condition affecting more than 100 million adults in the U.S., and it significantly impacts patients' quality of life while imposing billions of dollars of direct and indirect costs each year upon our healthcare system. Current diagnostic tests for GERD are highly invasive and medically inadequate, and the goal of this project is to develop a novel, minimally invasive Mucosal Impedance technique for more accurate detection of GERD while reducing costs.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 15
- Patients undergoing standard of care EGD with 48-hr pH testing by BRAVO
- Previous diagnosis of reflux
- At least 18 years of age
- Those less than 18 years of age
- Unable to give informed consent
- Use of acid suppressive therapy within the last 10 days
- Known history of Barrett's esophagus, gastric surgery, alcoholism, or significant motility condition
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Measurement of lower esophageal impedance using mucosal impedance catheter During standard of care EGD Mucosal impedance is obtained during routine care EGD and readings are compared to 48-hour Bravo capsule results. Mucosal impedance only takes one minute to perform during endoscopy.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States
Vanderbilt University Medical Center🇺🇸Nashville, Tennessee, United States